- Home
- XGN vs BRNS Comparison
XGN vs BRNS Comparison
Compare XGN & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- BRNS
- Stock Information
- Founded
- XGN 2002
- BRNS 2016
- Country
- XGN United States
- BRNS United Kingdom
- Employees
- XGN N/A
- BRNS N/A
- Industry
- XGN Medical Specialities
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- BRNS Health Care
- Exchange
- XGN Nasdaq
- BRNS Nasdaq
- Market Cap
- XGN 138.3M
- BRNS 36.0M
- IPO Year
- XGN 2019
- BRNS 2021
- Fundamental
- Price
- XGN $6.98
- BRNS $1.00
- Analyst Decision
- XGN Strong Buy
- BRNS Strong Buy
- Analyst Count
- XGN 2
- BRNS 1
- Target Price
- XGN $7.50
- BRNS $3.00
- AVG Volume (30 Days)
- XGN 248.8K
- BRNS 17.8K
- Earning Date
- XGN 08-04-2025
- BRNS 08-07-2025
- Dividend Yield
- XGN N/A
- BRNS N/A
- EPS Growth
- XGN N/A
- BRNS N/A
- EPS
- XGN N/A
- BRNS N/A
- Revenue
- XGN $56,724,000.00
- BRNS $14,969,000.00
- Revenue This Year
- XGN $18.92
- BRNS N/A
- Revenue Next Year
- XGN $14.78
- BRNS N/A
- P/E Ratio
- XGN N/A
- BRNS N/A
- Revenue Growth
- XGN 1.78
- BRNS 4381.74
- 52 Week Low
- XGN $1.78
- BRNS $0.64
- 52 Week High
- XGN $7.95
- BRNS $1.58
- Technical
- Relative Strength Index (RSI)
- XGN 52.18
- BRNS 55.94
- Support Level
- XGN $6.82
- BRNS $0.90
- Resistance Level
- XGN $7.15
- BRNS $1.10
- Average True Range (ATR)
- XGN 0.36
- BRNS 0.06
- MACD
- XGN -0.06
- BRNS 0.01
- Stochastic Oscillator
- XGN 37.07
- BRNS 60.00
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.